Tocagen (NASDAQ:TOCA) will be issuing its quarterly earnings data after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.
Tocagen (NASDAQ:TOCA) last announced its earnings results on Tuesday, August 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.25). The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $2.01 million. Tocagen had a negative return on equity of 77.46% and a negative net margin of 130,944.75%. On average, analysts expect Tocagen to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of TOCA stock traded down $0.03 during midday trading on Friday, hitting $11.28. 1,601 shares of the company were exchanged, compared to its average volume of 290,621. The company has a market capitalization of $212.08 million, a price-to-earnings ratio of -4.23 and a beta of 1.64. The company has a debt-to-equity ratio of 0.56, a quick ratio of 6.06 and a current ratio of 6.06. Tocagen has a 52 week low of $7.52 and a 52 week high of $15.80.
TOCA has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Tocagen from a “hold” rating to a “sell” rating in a report on Thursday, August 16th. Citigroup assumed coverage on shares of Tocagen in a research note on Tuesday, September 4th. They issued a “buy” rating and a $27.00 price objective for the company. BidaskClub cut shares of Tocagen from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. B. Riley lifted their price objective on shares of Tocagen from $15.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, September 20th. Finally, Chardan Capital assumed coverage on shares of Tocagen in a research note on Thursday, August 30th. They issued a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $20.75.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Recommended Story: How dollar cost averaging works
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.